Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. - Wikidata - awgldk - TriplyDB

Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.

Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.

http://www.wikidata.org/entity/Q34135209

about

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue.Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats.Potential uses of corticotropin-releasing hormone antagonists.Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia.Investigation of antiulcer and antioxidant activity of moclobemide in rats.Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders.Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.Role of corticotrophin releasing hormone in cerebral infarction-related gastrointestinal barrier dysfunction Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.

P2860

Q24655164-BA544B6A-F64F-441A-BF31-57F5C8F46FF8 Q24671910-43DCE3B4-13C3-4719-847D-59C932DCACAE Q30484216-3411FA48-8DE5-4797-8330-FA5EC5F8AF25 Q33448961-A5F1D302-B436-4707-A369-86267047AC5E Q34421388-42795138-C293-4F13-BA72-A5FA62622338 Q34587976-F5F820E7-751E-4520-8A7D-B95B449EB4DE Q34882307-6F3CF2D3-9D87-49F0-BC2E-99F290D795E4 Q35124879-C4FA17CB-0421-4497-B54C-44892BC38BF2 Q35937847-428F751E-964C-45C3-9FD1-E379B8F52CA7 Q37264524-B572587D-81A7-42B4-A819-1605D18ADFEB Q38831882-C3A3D6CD-24F9-4CD6-B1F3-781DB16BA65E Q41818798-DCBD2430-3A69-4413-A579-26AC0C5A4D3E Q42533202-9D310C60-7C18-4129-8729-FB37FBFB61EA

P2860

Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.

http://www.wikidata.org/entity/Q34135209

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Marked suppression of gastric ...... ess by a novel class of drugs.

@ast

Marked suppression of gastric ...... ess by a novel class of drugs.

@en

Marked suppression of gastric ...... ess by a novel class of drugs.

@nl

type

label

Marked suppression of gastric ...... ess by a novel class of drugs.

@ast

Marked suppression of gastric ...... ess by a novel class of drugs.

@en

Marked suppression of gastric ...... ess by a novel class of drugs.

@nl

prefLabel

Marked suppression of gastric ...... ess by a novel class of drugs.

@ast

Marked suppression of gastric ...... ess by a novel class of drugs.

@en

Marked suppression of gastric ...... ess by a novel class of drugs.

@nl

P1433

Q34135209-E53F0789-6BDB-42DD-9B6E-21B6D17DC656

P1476

Q34135209-77F1F21B-987C-4873-A076-A97C0B966B15

P2093

Q34135209-315D9802-C8C7-43CE-A1BA-0460047A89B7

Q34135209-522395AA-7E90-4E5F-B8C7-E277370351F4

Q34135209-723CCAE2-D3FA-473E-B0B8-0E57A495F50D

Q34135209-88491FAD-C8A5-41A2-896B-D84BBC5FC726

Q34135209-88741EF3-70DF-435F-8BF5-7139041E6800

Q34135209-8F76F407-F196-4C02-88DE-18D08FE02A82

Q34135209-B4251233-9766-4669-846E-F6EF9BDB7D1D

Q34135209-E0C129AB-5412-4D9B-B273-E4F88B011C73

Q34135209-F7FAC29C-8A4B-4BFF-8332-CBA0828B6101

P2860

Q34135209-01E7E4F0-8177-4308-8B5F-2B88A10D9D9F

Q34135209-04178C0E-D869-47F2-BF0D-8B6220C52A76

Q34135209-056BF8DF-CD61-4DBF-94A3-FE65A2CC2EF6

Q34135209-0700D1FC-FD3A-4EBE-B3E3-BC7629CEBBED

Q34135209-09C13B49-B2BD-459A-B7A8-7974D88B03CA

Q34135209-0E7C6220-EE52-4E4A-8548-B12E6BEB1FAC

Q34135209-0FA7F291-1FEC-4A7B-99BE-B697404EE6E6

Q34135209-13E6701B-0F95-4AAB-BD53-14840E47E5AB

Q34135209-1841727A-2575-4EBF-9909-4334ABF69E28

Q34135209-1FF61D24-C191-4AC9-AC57-76471DC2D985

P2888

Q34135209-0099520E-DEF8-4F70-849F-99B4ACF594E8

P304

Q34135209-BEB18581-5031-4DF3-98F7-1F011FD293F5

P31

Q34135209-7AEEE4FA-059C-4FE7-975E-BAFDF8F9DB51

P356

Q34135209-EA3CC804-D36D-4BA7-864D-5FB574802610

P407

Q34135209-7B055628-6E27-4E9E-BC29-2843C613BA4E

P433

Q34135209-4651797A-D383-4555-AF70-FDCE25514422

P478

Q34135209-4BE573EE-2A1A-455E-913E-430618B0E5C2

P577

Q34135209-376036BE-5489-48E3-B6D8-8D9950F0C4D6

P5875

Q34135209-44180176-C208-4E59-88D8-902FFE1EF4C4

P698

Q34135209-9C3CDA85-2AD4-4478-956D-8141E503BD80

P356

P1433

Molecular Psychiatry

P1476

Marked suppression of gastric ...... ess by a novel class of drugs.

@en

P2093

Chrousos GP

http://www.w3.org/2001/XMLSchema#string

Gabry KE

http://www.w3.org/2001/XMLSchema#string

Gold PW

http://www.w3.org/2001/XMLSchema#string

McCann SM

http://www.w3.org/2001/XMLSchema#string

Mostafa RM

http://www.w3.org/2001/XMLSchema#string

Negrao AB

http://www.w3.org/2001/XMLSchema#string

Rice KC

http://www.w3.org/2001/XMLSchema#string

Sternberg E

http://www.w3.org/2001/XMLSchema#string

Webster EL

http://www.w3.org/2001/XMLSchema#string

P2860

Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis

Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa

Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials.

Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact.

Neuroendocrinology of stress.

Stress-induced gastric ulceration: its aetiology and clinical implications.

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome.

P2888

P304

474-83, 433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MP.4001031

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11291853

http://www.w3.org/2001/XMLSchema#string

P698

12082565

http://www.w3.org/2001/XMLSchema#string